The following is a summary of "Bronchiectasis In Patients With Inflammatory Bowel Diseases – Prevalence, Predictors, And ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...

Visakhapatnam: Researchers at the department of forensic medicine and toxicology at Andhra Medical College, Visakhapatnam, conducted an in-depth analy.

Fortis Hospital, Anandapur has launched the dedicated lung failure clinic, a first-of-its-kind super-specialty outpatient service tailored to patients battling chronic and progressive respiratory ...

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.

One of the most striking claims in the review is that AI-based classification models can meet or exceed the performance of ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...

AstraZeneca to showcase innovation in infectious disease protection at ESCMID Global 2025: Cambridge, UK Thursday, April 10, 2025, 15:00 Hrs [IST] AstraZeneca will share new data ...